Galectin Therapeutics Inc

Galectin Therapeutics develops belapectin, a carbohydrate-based galectin-3 inhibitor for metabolic dysfunction-associated steatohepatitis with cirrhosis and portal hypertension, and combination immunotherapy for advanced head and neck cancers and other malignancies.